Skip to main content

A

Stock
Health Care
Diagnostics & Research

Performance overview

A Price
Price Chart

Forward-looking statistics

Beta
0.72
Risk
25.64%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees37K
Market cap$38.8B

Fundamentals

Enterprise value$35.7B
Revenue$6.6B
Revenue per employee—
Profit margin17.59%
Debt to equity60.04

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$4.05
Dividend per share$0.99
Revenue per share$23.18
Avg trading volume (30 day)$241M
Avg trading volume (10 day)$199M
Put-call ratio—

Macro factor sensitivity

Growth+0.2
Credit+5.6
Liquidity-0.5
Inflation-3.1
Commodities-0.1
Interest Rates-1.4

Valuation

Dividend yield0.82%
PEG Ratio21.48
Price to sales5.20
P/E Ratio21.48
Enterprise Value to Revenue5.39
Price to book5.62

Upcoming events

Next earnings dayMay 29, 2025
Next dividend day—
Ex. dividend dayJuly 1, 2025

News

Nvidia CEO: If I were a 20-year-old again today, this is the field I would focus on in college

If Nvidia CEO Jensen Huang were a student today, he says he'd focus on the physical sciences.

CNBC International TV (July 22, 2025)
AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

AstraZeneca has become the latest pharma firm to announce a multi-billion investment in the U.S. The Anglo-Swedish biotech firm has committed to spend $50 billion by 2030.

CNBC (July 22, 2025)
'PARC' is representative of what has been going on in this market, says Jim Cramer

'Mad Money' host Jim Cramer talks the state of the 'two-track' market.

CNBC Television (July 21, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free